Lung Cancer

Crofton and Douglas's Respiratory Diseases: Fifth Edition

Volumn 2, Issue , 2008, Pages 1077-1123

  Fergusson, Ronald J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carcinoma; Lung cancer; Mortality; Smoking; Tobacco consumption

Indexed keywords

EID: 84886449179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470695999.ch41     Document Type: Chapter

References (303)

1. Cancer Research Campaign. Factsheet II:Lung cancer and smoking. Factsheet V:Cancer in the European Community. London: CRC, 1992.
2. Charlton A. Tobacco and lung cancer. In:Thatcher N, Spiro S, eds. New Perspectives in Lung Cancer. London: BMJ Publishing Group, 1994: 1.
3. Belcher JR. The changing pattern of bronchial carcinoma. Br J Dis Chest 1987; 81:87.
4. Surgeon General. The Health Consequences of Smoking. Washington, DC: Government Printing Office, 1982.
5. Royal College of Physicians. Health or Smoking? London: Pitman Medical, 1983.
6. International Agency for Research on Cancer. Tobacco Smoking. Geneva: World Health Organization, 1986.
7. Doll R, Hill AB. Astudy of the aetiology of carcinoma of the lung. Br Med J 1952; 2: 1271.
8. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976; 2: 1525.
9. Enstrom JE. Trends in mortality among California physicians after giving up smoking:1950-79. Br Med J 1983; 286: 1101.
10. Doll R, Gray R, Hafner B et al. Mortality in relation to smoking: 22 years' observations on female British doctors. Br Med J 1980; 280:967.
11. Kahn HA. The Dorn Study of Smoking and Mortality among US Veterans: Report on 81/2 Years of Observation. Washington, DC:Government Printing Office, 1966.
12. Bross IDJ, Gibson R. Risks of lung cancer in smokers who switch to filter cigarettes. Am J Public Health 1968; 58: 1396.
13. Doll R, Hill AB. Mortality in relation to smoking: ten years' observations of British doctors. Br Med J 1964; 1: 1399, 1460.
14. Hirayama T. Cancer mortality in non-smoking women with smoking husbands in a large scale cohort study in Japan. Prev Med 1984; 13: 680.
15. Janerich DT, Thompson WD, Varela LR et al. Lung cancer and exposure to tobacco smoke in the household. N Engl J Med 1990; 323:632.
16. Wald N, Kiryluk S, Darby S et al. UK Smoking Statistics. Oxford: Oxford University Press, 1988.
17. Office of Population Censuses and Surveys. Cigarette smoking 1972-1990. In: General Household Survey. London: HMSO, 1991.
18. Stanley K, Stjernsward J. Lung cancer in developed and developing countries. In:Hansen HH, ed. Basic and Clinical Concepts of Lung Cancer. Boston: Kluwer Academic Publishers, 1989: 1.
19. Report of a Task Group. Air pollution and cancer: risk assessment methodology and epidemiological evidence. Environ Health Perspect 1978; 22: 1.
20. Doll R. Atmospheric pollution and lung cancer. Environ Health Perspect 1978; 22: 23.
21. Axelson O. Occupational and environmental exposure to radon: cancer risks. Annu Rev Public Health 1991; 12: 235.
22. Pershagen G, Liang ZH, Hrubec Z et al. Residential radon exposure and lung cancer in Swedish women. Health Phys 1992; 63: 179.
23. Pershagen G, Akerblom G, Axelson O et al. Residential radon exposure and lung cancer in Sweden. N Engl J Med 1994; 330: 159.
24. Saracci R. Asbestos and lung cancer: an analysis of the epidemiological evidence on the asbestos-smoking interaction. Int J Cancer 1977; 20: 323.
25. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 1979; 330: 473.
26. de Vos Irvine H, Lamont DW, Hole DJ et al. Asbestos in lung cancer in the West of Scotland. Br Med J 1993; 306: 1503.
27. Meredith SK, McDonald JC. Work related respiratory disease in the United Kingdom 1989-92: a report on the SWORD project. Occup Med 1994; 44: 183.
28. Samet JM, Cutvirt DM, Waxweiler RJ et al. Uranium mining and lung cancer in Navajo men. N Engl J Med 1984; 310: 1481.
29. De Villiers AJ, Windish JP. Lung cancer in a fluorspar mining community. 1. Radiation, dust and mortality experience. Br J Ind Med 1964; 21: 94.
30. Radford EPST, Clair Renard KG. Lung cancer in Swedish iron miners exposed to low doses of radon daughters. N Engl J Med 1984; 310: 1485.
31. Fox AK, Goldblatt P, Kinlen LJ. Astudy of the mortality of Cornish tin miners. Br J Ind Med 1981; 38: 378.
32. Doll R, Matthews ID, Morgan LG. Cancers of the lung and nasal sinuses in nickel workers: a reassessment of the period of risk. Br J Ind Med 1977; 34: 102.
33. Alderson MR, Rattun NE, Bustrup L. Health of workmen in the chromate-producing industry in Britain. Br J Ind Med 1981; 38:117.
34. Lee AM, Fraumeni JF. Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst 1969; 42: 1045.
35. McCallam RL, Wooley V, Petrie A. Lung cancer associated with chloromethyl methyl ether manufacture: an investigation of two factories in the United Kingdom. Br J Ind Med 1983; 40: 384.
36. Hurley JF, Archibald RM, Collins PL et al. The mortality of coke workers in Britain. Am J Ind Med 1983; 4: 691.
37. Ask-Upmark E. Bronchial carcinoma in printing workers. Dis Chest 1955; 27: 427.
38. Browne K. Is asbestos or asbestosis the cause of the increased risk of lung cancer in asbestos workers? Br J Ind Med 1986; 43: 145.
39. Hughes JM, Weill H. Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. Br J Ind Med 1991; 48: 229.
40. Wilkinson P, Hansell DM, Janssens J et al. Is lung cancer associated with asbestos exposure when there are no small opacities on the chest radiograph? Lancet 1995; 345: 1074.
41. Turner-Warwick M, Lebowitz M, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496.
42. Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974; 29: 247.
43. Chaudhuri MR. Primary pulmonary scar carcinomas. Ind J Med Res 1973; 61: 858.
44. Ochs RH, Katz AS, Edmunds LH et al. Prognosis of pulmonary scar carcinoma. J Thorac Cardiovasc Surg 1982; 84: 359.
45. Prichard MG, Brown PJE, Sterret GF. Bronchioloalveolar carcinoma arising in longstanding lung cysts. Thorax 1984; 39:545.
46. World Health Organization. International histological classification of tumours, no. 1. In: Histological Typing of Lung Tumours, 2nd edn. Geneva: WHO, 1981.
47. Carter N, Nelson F, Gosney JR. Ultrastructural heterogeneity in undifferentiated bronchial carcinoma. J Pathol 1993; 171: 53.
48. Edwards CW. Current concepts in pathology:carcinoma of the lung. Clin Oncol 1994; 6: 319.
49. Lamb D. Histological classification of lung cancer. Thorax 1984; 39: 161.
50. Thomas JStJ, Lamb D, Ashcroft T et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report a UK CCCR Lung Cancer Working Party. Thorax 1993; 48:1135.
51. Carter D. Squamous cell carcinoma of the lung: an update. Semin Diagn Pathol 1984; 2:226.
52. Edwards C. Pulmonary adenocarcinoma:a review of 106 cases and a proposed new classification. J Clin Pathol 1987; 40: 125.
53. Carney DN. Biology of small cell lung cancer. Lancet 1993; 339: 843.
54. Fergusson RJ, Smyth JF. Studying lung cancer in the laboratory. I. Development of model systems. Thorax 1989; 42: 753.
55. Woll PJ. Growth factors and lung cancer. In:Thatcher N, Spiro S, eds. New Perspectives in Lung Cancer. London: BMJ Publishing Group, 1994: 51.
56. Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastric releasing polypeptide. Cancer Res 1987; 47: 821.
57. Alexander RW, Upp JR, Poston GJ et al. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 1988; 48: 1439.
58. Cuttita F, Carney DN, Mulshine J et al. Bombesin like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985; 316: 823.
59. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res 1991; 51: 3621.
60. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87: 3294.
61. Putnam EA, Yen N, Gallick GE et al. Autocrine growth stimulation by TGF-alpha in human non-small cell lung cancer. Surg Oncol 1992; 1: 49.
62. Law MR. Genetic predisposition to lung cancer. Br J Cancer 1990; 61: 195.
63. Bench A, Rabbitts P. Genetic changes in lung cancer. In: Thatcher N, Spiro S, eds. New Perspectives in Lung Cancer. London: BMJ Publishing Group, 1994: 19.
64. Whang-Peng J, Bunn PAKAO, Shan CS et al. Anon-random chromosomal abnormality, del 3p (14-23) in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 1982; 6: 119.
65. Naylor SL, Johnson BE, Minna JD et al. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987; 329: 451.
66. Harbour JW, Lai S-L, Whang-Peng J et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1989; 241: 353.
67. Rabbits P, Douglas J, Daly M et al. Frequency and extent of the allelic loss in the short arm of chromosome 3 in non-small cell lung cancer. Genes Chrom Cancer 1989; 1: 95.
68. Yokoyama S, Yamakawa K, Tsuchiya E et al. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 1992; 52: 873.
69. Johnson BE, Kelley MJ. Biology of small cell lung cancer. Lung Cancer 1995; 12 (Suppl 3):S5.
70. Roth JA. Molecular events in lung cancer. Lung Cancer 1995; 12 (Suppl 2): S3.
71. Slebos RJC, Kibbelaar RE, Dalesio O et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561.
72. Anderson MLM, Spandidos DA. Oncogenes and onco-suppressor genes in lung cancer. Respir Med 1993; 87: 413.
73. Souhami RL, Beverley PCL, Bobrow LG et al. Results of central data analysis: 2nd International Workshop on Small Cell Lung Cancer Antigens. J Natl Cancer Inst 1991; 83: 609.
74. Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med 1995; 89: 587.
75. Johnson PWM, Joel SP, Love S et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993; 67: 760.
76. Manning JT, Spjurt HJ, Tschen JA. Bronchioloalveolar carcinoma. Cancer 1984; 54: 525.
77. Lam WK, So SY, YUDYC. Clinical features of bronchogenic carcinoma in Hong Kong:review of 480 patients. Cancer 1983; 52: 369.
78. Fergusson RJ, Gregor A, Dodds R et al. Management of lung cancer in South-East Scotland. Thorax 1996; 51: 569.
79. Weiss W, Boucot KR. The Philadelphia pulmonary neoplasm research project: early roentgenographic appearance of bronchogenic carcinoma. Arch Intern Med 1974; 134: 306.
80. Fontana RS, Sanderson DR, Woolner LB et al. The Mayo lung project for early detection and localisation of bronchogenic carcinoma:a status report. Chest 1975; 67: 511.
81. Byrd RB, Carr DT, Miller WE et al. Radiographic abnormalities in carcinoma of the lung as related to histological cell type. Thorax 1969; 24: 573.
82. Harold JT. Lymphangitis carcinomatosa of the lungs. Q J Med 1952; 21: 353.
83. Watson WL, Farpour A. Terminal bronchiolar or 'alveolar cell' cancer of the lung: two hundred and sixty-five cases. Cancer 1966; 19: 776.
84. di Bonito L, Colautti I, Patriavca S et al. Cytological typing of primary lung cancer:study of 100 cases with autopsy confirmation. Diagn Cytopathol 1991; 7: 7.
85. Clee MD, Sinclair DJM. Assessment of factors influencing the result of sputum cytology in bronchial carcinoma. Thorax 1981; 36: 143.
86. Rosa UW, Prolla JL, Gastal ES. Cytology in diagnosis of cancer affecting the lung:results in 1000 consecutive patients. Chest 1973; 63: 203.
87. Evans DMD, Shelley G. Respiratory cytodiagnosis:study in observer variation and its relation to quality of material. Thorax 1982; 37: 259.
88. Radke JR, Conway WA, Eyler WR. Diagnostic accuracy in peripheral lung lesions:factors predicting success with flexible fiberoptic bronchoscopy. Chest 1975; 76: 176.
89. Wang KP, Marsh BR, Summer WE et al. Transbronchial needle aspiration for diagnosis of lung cancer. Chest 1981; 80: 48.
90. Gass GD, Olsen GN. Pre-operative pulmonary function testing to predict postoperative morbidity and mortality. Chest 1986; 89: 127.
91. Wernly JA, De Meester TR, Kirchner PT et al. Clinical value of quantitative ventilation- perfusion lung scans in the surgical management of bronchogenic carcinoma. J Thorac Cardiovasc Surg 1980; 80: 535.
92. Corris PA, Ellis DA, Hawkins T et al. Use of radionuclide scanning in the pre-operative estimation of pulmonary function after resection. Thorax 1987; 42: 285.
93. Kerr KM, Lamb D, Wathen CG et al. Pathological assessment of mediastinal lymph nodes in lung cancer: implications for noninvasive mediastinal staging. Thorax 1992; 47: 337.
94. McLeod TC, Bourgouin PM, Greenberg RW et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182: 319.
95. Staples CA, Muller NL, Miller RR et al. Mediastinal nodes in bronchogenic carcinoma:comparison between CT and mediastinoscopy. Radiology 1988; 167: 367.
96. Webb WR, Gatson SC, Zerhouni E et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma. Report of the Radiographic Diagnostic Oncology Group. Radiology 1991; 178: 705.
97. Dales RE, Stark R, Sanicaranarayanan R. Computed tomography to stage lung cancer: approaching a controversy using meta analysis. Am Rev Respir Dis 1990; 141:1096.
98. Arita T, Kuramitsu T, Kawamura M et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995; 50: 1267.
99. Goldstraw P, Kurzer M, Edwards D. Preoperative staging of lung cancer: accuracy of computed tomography versus mediastinoscopy. Thorax 1983; 38: 10.
100. Lowe VJ, Naunheim KS. Current role of positron emission tomography in thoracic oncology. Thorax 1998; 53: 703.
101. Tsang GMK, Watson DCT. The practice of cardiothoracic surgeons in the pre-operative staging of non-small cell lung cancer. Thorax 1992; 47: 3.
102. Kunstek N, Cicin-Sain S, Kausic M et al. The ultrasonic diagnosis of focal liver lesions:findings compared to CT. Recent Adv Ultrasound 1981; 3: 320.
103. Hooper RG, Beechler CR, Johnson MC. Radioisotope scanning in the initial staging of bronchogenic carcinoma. Am Rev Respir Dis 1978; 118: 279.
104. Ramsdell JW, Peters RM, Taylor AT et al. Multi-organ scanning for staging lung cancer. J Thorac Cardiovasc Surg 1977; 73: 653.
105. Michel F, Soler M, Imhop E et al. Initial staging of non-small cell lung cancer. Thorax 1991; 46: 469.
106. Levenson RM, Sauerbrunn BJL, Ihde DC et al. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. Am J Roentgenol 1981; 137: 31.
107. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest and abdomen in the pre-operative assessment of non-small cell lung cancer. Thorax 1988; 43:883.
108. Newman SJ, Hansen HH. Frequency, diagnosis and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974; 33: 492.
109. Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49: 14.
110. Muers MF. Pre-operative screening for metastases in lung cancer. Thorax 1994; 49: 1.
111. Muers MF. How much investigation? In:Thatcher N, Spiro S, eds. New Perspectives in Lung Cancer. London: BMJ Publishing Group, 1994: 77.
112. Mountain CF, Carr DT, Anderson WAD. System for the clinical staging of lung cancer. Am J Roentgenol 1974; 120: 130.
113. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710.
114. Rawson NBS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the sub-committee for the management of lung cancer of the UK CCCR. Br J Cancer 1990; 61: 597.
115. Edinburgh Lung Cancer Group. Patients presenting with lung cancer in South East Scotland. Thorax 1987; 42: 853.
116. Bignall JR, Martin M, Smithers DW. Survival of 6086 cases of bronchial carcinoma. Lancet 1967; i: 1067.
117. Walker WS, Carnochan FM, Tin M. Thoracoscopy assisted pulmonary lobectomy. Thorax 1993; 48: 921.
118. McKenna RJ. Lobectomy by video-assisted thoracic surgery with mediastinal node sampling for lung cancer. J Thorac Cardiovasc Surg 1994; 107: 879.
119. Ginsberg RJ, Hill LD, Eagen RT et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983; 86: 654.
120. Yellin A, Benfield JR. Surgery for bronchogenic carcinoma in the elderly. Am Rev Respir Dis 1985; 131: 197.
121. Mountain CF, Lukeman JM, Hammar SP et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trial population. J Surg Oncol 1987; 35: 147.
122. Stanley KE. Experience of the Ludwig Lung Cancer Study Group. Chest 1986; 89 (Suppl 4): 343S.
123. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIa disease. Chest 1990; 97: 1045.
124. Feld R, Rubenstein LV, Weisenberger TH. Sites of recurrence in resected stage I nonsmall cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2: 1352.
125. Smart J, Hilton G. Radiotherapy of cancer of the lung: Results in a selected group of cases. Lancet 1956; i: 880.
126. Morrison R, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus: a clinical trial to compare surgery and supervoltage radiotherapy. Lancet 1963; i: 683.
127. Dobbs HJ, Parker RP, Hodson NJ et al. The use of CT in radiotherapy treatment planning. Radiother Oncol 1983; 1: 133.
128. Cox JD. Non-small cell lung cancer, role of radiation therapy. Chest 1986; 89: 284S.
129. Lee RE, Carr DT, Childs DS. Comparison of split-course radiation therapy and continuous radiation therapy for unresectable bronchogenic carcinoma: 5 year results. Am J Roentgenol 1976; 126: 116.
130. Cox P, Kennelly GM. The role of curative radiotherapy in the treatment of lung cancer. Cancer 1980; 45: 698.
131. Deeley TJ, Singh SP. Treatment of inoperable carcinoma of the bronchus by megavoltage X-rays. Thorax 1967; 22: 562.
132. Graham PH, Gebski VJ, Langlands AO. Radical radiotherapy for early non small cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 31: 261.
133. Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of Stage I non small cell lung cancer. Chest 1995; 108: 1278.
134. Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART). Eur J Cancer 1990; 26: 927.
135. Dische S, Saunders M. Continuous, hyperfractionated, accelerated radiotherapy (CHART). An interim report upon late morbidity. Radiother Oncol 1989; 16: 67.
136. Saunders M, Dische S, Grosch E et al. Experience with CHART. Int J Radiat Oncol Biol Phys 1991; 21: 871.
137. Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non small cell lung cancer: a randomised multicentre trial. Lancet 1997; 350: 161.
138. Priestman TJ, Bullimore JA, Godden TP et al. The Royal College of Radiologists' Fractionation Survey. Clin Oncol 1989; 1: 39.
139. Medical Research Council. Inoperable non-small cell lung cancer. MRC randomised trial of palliative radiotherapy with 2 fractions or 10 fractions. Br J Cancer 1991; 63: 265.
140. MRC Lung Cancer Working Party. An MRC randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992; 65: 934.
141. Line D, Deeley TJ. Palliative therapy. In:Deeley TJ, ed. Carcinoma of the Bronchus. New York: Appleton-Century-Crofts, 1972.
142. Slawson RG, Scott RM. Radiation therapy in bronchogenic carcinoma. Radiology 1979; 132: 175.
143. Ryan GF, Ball DL, Smith JG. Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys 1995; 31: 273.
144. Priestman TJ, Dunn J, Brada M et al. Final results of the Royal College of Radiologists' Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 1996; 8: 308.
145. Gilbert RW, Kim J, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978; 3: 40.
146. McBeth F. Radiotherapy in the treatment of lung cancer. Br J Hosp Med 1996; 55: 639.
147. Rubin P, Casarett GW. Clincal Radiation Pathology. Philadelphia: WB Saunders, 1968.
148. Lawson RAM, Ross WM, Gold RG et al. Post-radiation pericarditis: report on four more cases with special reference to bronchogenic carcinoma. J Thorac Cardiovasc Surg 1972; 63: 841.
149. Hetzel MR, Smith SGT. Endoscopic palliation of tracheobronchial malignancies. Thorax 1991; 46: 325.
150. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899.
151. Vokes EE. Should non-small cell carcinoma of the lung be treated by chemotherapy? Pro: chemotherapy is for NSCLC. Am J Respir Crit Care Med 1995; 151: 1285.
152. White SR. Therapeutic empiricism: the case against chemotherapy in non-small cell lung cancer. Am J Respir Crit Care Med 1995; 151:1288.
153. Bromley LL, Szur L. Combined radiotherapy and resection for carcinoma of the bronchus: experiences with 66 patients. Lancet 1955; ii: 937.
154. Warram J. Pre-operative irradiation of cancer of the lung: final report of a therapeutic trial, a collaborative study. Cancer 1975; 36: 914.
155. Weisenburger TH, Gail M for the Lung Cancer Study Group. Effects of postoperative mediastinal irradiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315: 1377.
156. MRC Lung Cancer Working Party. Randomized trial of surgical resection with or without post-operative radiotherapy in NSCLC. Lung Cancer 1994; 11 (Suppl 1): 148.
157. PORTMeta-analysis Trialist Group. Post operative radiotherapy in non small cell lung cancer: systemic review and metanalysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257.
158. Jaklitsch MT, Strauss GM, Healey EA. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl 2): S17.
159. Ginsberg RJ. Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl 2): S33.
160. Burkes RL, Ginsberg RJ, Shepherd FA et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto Phase II trial. J Clin Oncol 1992; 10: 580.
161. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for Stage IIIA (N2) lung cancer: the Memorial Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365.
162. Roth JAQ, Fossella F, Komaki R et al. A randomized trial comparing peri-operative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86:673.
163. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing pre-operative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153.
164. Milroy R, MacBeth F. Neoadjuvant chemotherapy in Stage IIIA non-small cell lung cancer. Thorax 1995; 50 (Suppl 1): S25.
165. Schaake-Konig C, Van Den Bogaert W, Dalesia O et al. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall cell lung cancer. N Engl J Med 1992; 326: 524.
166. Bishop JF. Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl 2): S53.
167. Leonard RCF. Small cell lung cancer. Br J Cancer 1989; 59: 487.
168. Spiro SG. Chemotherapy of small cell lung cancer. Clin Oncol 1985; 4: 105.
169. Oldham RK. Small cell lung cancer: a curable disease. Clin Oncol 1985; 4: 153.
170. Lassen UN, Hirsch FR, Osterlind K et al. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer 1998; 20: 151.
171. Mehta C, Vogl SE. High dose cyclophosphamide in the induction chemotherapy of small cell lung cancer: minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 1982; 23: 155.
172. Humblet Y, Symann M, Bosly A et al. Late intensification with autologous bone marrow transplantation for small cell lung cancer: a randomised trial. Proc Am Soc Clin Oncol 1985; 4: 176.
173. Thatcher N. Haematopoietic growth factors and lung cancer. Thorax 1992; 47: 119.
174. MRC Lung Cancer Working Party. Controlled trial of 12 versus 6 courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989; 59: 584.
175. MRC Lung Cancer Working Party. Arandomised trial of 3 or 6 courses of etoposide, cyclophosphamide, methotrexate and vincristine or 6 courses of etoposide and ifosfamide in small cell lung cancer I: survival and prognostic factors. Br J Cancer 1993; 68:1150.
176. Spiro SG, Souhami RL, Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59: 578.
177. Abeloff MD, Klastersky J, Drings PD et al. Complications of treatment of small cell carcinoma of the lung. Cancer Treat Rep 1983; 67:21.
178. Feld R. Complications in the treatment of small cell carcinoma of the lung. Cancer Treat Rev 1981; 8: 5.
179. Pizzo PA, Robichaud KJ, Gill FA et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194.
180. Bleehan NM, Fayers PM, Girling DJ et al. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell lung cancer. Respir Med 1989; 83:51.
181. Postmus PE, Smit EF. Oral therapy for small cell lung cancer. Lung Cancer 1995; 12 (Suppl 3): S63.
182. Carney DN, Grogan L, Smit EF et al. Single agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17 (Suppl 2): 49.
183. MRC Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Lancet 1996; 348: 563.
184. Souhami RL, Geddes DM, Spiro SG et al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J 1984; 288: 1643.
185. Perez CA, Einhorn L, Oldham FA et al. Randomised trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984; 2: 1200.
186. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited disease small cell carcinoma of the lung. N Engl J Med 1987; 316:912.
187. Arriagada RLE, Chevalier T, Ruffie P et al. Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 1135.
188. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618.
189. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890.
190. Turrisi AT. Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Lung Cancer 1995; 12 (Suppl 3):S41.
191. Arriagada R, Kramer ALE, Chevalier T et al. Competing events determining relapse-free survival in limited small cell lung carcinoma. J Clin Oncol 1992; 10: 447.
192. Roth BJ, Johnson DH, Lawrence HE et al. Randomised study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer. Aphase III trial of the South-Eastern Cancer Study Group. J Clin Oncol 1992; 10:282.
193. Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 1993; 11:336.
194. Brooks BJ, Seifter EJ, Walsh TE et al. Pulmonary toxicity with combined modality therapy for limited small cell lung cancer. J Clin Oncol 1986; 4: 710.
195. Pedersen AG. Diagnosis of CNS metastases from SCLC. In: Hanson HH, ed. Lung Cancer: Basic and Clinical Aspects. Dordrecht:Martinus Nijhoff, 1986: 153.
196. Nujent JL, Bunn PA, Matthews M et al. CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening of survival. Cancer 1979; 44: 1885.
197. Felletti R, Souhami RL, Spiro SG et al. Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol 1985; 4: 335.
198. Kristjansen PEG, Hansen HH. Prophylactic cranial irradiation in small cell lung cancer:an update. Lung Cancer 1995; 12 (Suppl 3):S23.
199. Seydel HG, Greech R, Pagano M et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol 1985; 8: 218.
200. Licciardello JTW, Cersosimo RJ, Karp DD et al. Disturbing central nervous system complications following combination chemotherapy and prophylactic whole brain irradiation in patients with small cell lung cancer. Cancer Treat Rep 1985; 69: 1429.
201. Turrisi AT. Brain irradiation and systemic chemotherapy for small cell lung cancer. Dangerous liaisons? J Clin Oncol 1990; 8: 196.
202. Arriagada RLE, Chevalier T, Borie F et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87: 183.
203. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992; 10: 1498.
204. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow up. Lancet 1973; ii: 63.
205. Shields TW, Higgins GA, Matthews MJ et al. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982; 84: 481.
206. Higgins GA, Shields TW, Keehn RJ. The solitary pulmonary nodule: ten year follow up of Veterans Administration-armed forces co-operation study. Arch Surg 1975; 110: 570.
207. Holmes EC. The role of surgery in small cell carcinoma of the lung (SCLC). Lung Cancer 1995; 12 (Suppl 3): S17.
208. Baker PB, Ettinger DS, Ruckdeschel JD et al. The role of surgery in the management of selected patients with small cell carcinoma of the lung. J Clin Oncol 1987; 5: 697.
209. Meyer JA, Gullo JJ, Ikins PM et al. Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1989; 97: 177.
210. Prager RL, Foster S, Hainsworth JD et al. The feasibility of 'adjuvant surgery' in limited stage small cell carcinoma: a prospective evaluation. Ann Thorac Surg 1984; 28: 622.
211. Shepherd FA, Ginsberg R, Patterson GA et al. Is there ever a role for salvage operations in limited small cell lung cancer? J Thorac Cardiovasc Surg 1991; 101: 196.
212. Ladd T, Piantidosi S, Thomas P et al. A prospective randomised trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; 106: 3205.
213. Maurer LH. Ectopic hormone syndromes in small cell carcinoma of the lung. Clin Oncol 1985; 4: 67.
214. Posner JB. Non-metastatic effects of cancer on the nervous system. In: Wyngaarden JB, Smith LH, eds, Textbook of Medicine. Philadelphia: WB Saunders, 1982.
215. Henson RA, Urich H. Cancer and the nervous system. In: The Neurological Manifestations of Systemic Malignant Disease. Oxford: Blackwell Scientific Publications, 1982.
216. Rassam JW, Anderson G. Incidence of paramalignant disorders in bronchogenic carcinoma. Thorax 1975; 30: 86.
217. Stevenson JC. Malignant hypercalcaemia. Br Med J 1985; 291: 421.
218. Ralston SH, Fogelman I, Gardner MD et al. Hypercalcaemia of malignancy: evidence for a non-parathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci 1984; 66: 187.
219. Ralston SH. Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surv 1994; 21: 179.
220. Jamieson MJ. Hyponatraemia. Br Med J 1985; 290: 1723.
221. Forrest JN, Cox M, Hong C et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298: 173.
222. Schrier RW. Treatment of hyponatremia. N Engl J Med 1985; 312: 1121.
223. Hainsworth JD, Workman R, Greco FA. Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer 1983; 51: 161.
224. Littlewood TJ, Smith AP. Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin. Thorax 1984; 39: 636.
225. Sheppard F, Laskey J, Evans W et al. Cushing's syndrome associated with ectopic corticotrophin production and small cell lung cancer. J Clin Oncol 1992; 10: 21.
226. Bondy PK, Gilby ED. Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer 1982; 50: 2147.
227. Eisen T, Hickish T, Smith IE et al. Small cell lung cancer. Lancet 1995; 345: 1285.
228. Sachs BA, Becker N, Bloomberg AE et al. 'Cure' of ectopic ACTH syndrome secondary to adenocarcinoma of the lung. J Clin Endocrinol Metab 1970; 30: 590.
229. Hoffman D, Brigham B. The use of ketaconazole in ectopic adrenocorticotrophic hormone syndrome. Cancer 1991; 67: 1447.
230. Schumacher HR. Articular manifestations of hypertrophic pulmonary osteoarthropathy in bronchogenic carcinoma. Arthritis Rheum 1976; 19: 629.
231. Hammarsten JF, O'Leary J. The features and significances of hypertrophic osteoarthropathy. Arch Intern Med 1957; 99: 431.
232. Green N, Kurohara SS, George FW, Crews QE. The biologic behavior of lung cancer according to histologic type. Radiol Clin Biol 1972; 41: 160.
233. Yacoub MH. Relation between the histology of bronchial carcinoma and hypertrophic pulmonary osteoarthropathy. Thorax 1965; 20: 537.
234. Gall EA, Bennett GA, Bauer W. Generalised hypertrophic osteoarthropathy: a pathologic study of seven cases. Am J Pathol 1951; 27:349.
235. Flavell G. Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy. Lancet 1956; i: 260.
236. Rabson AS, Rosen SW, Tashjian AH et al. Production of human chorionic gonadotrophin in vitro by a cell line derived from a carcinoma of the lung. J Natl Cancer Inst 1973; 50: 669.
237. Healy TM. Eosinophilia in bronchogenic carcinoma. N Engl J Med 1974; 291: 794.
238. Knox AJ, Johnson CE, Page RL. Eosinophilia associated with thoracic malignancy. Br J Dis Chest 1986; 80: 92.
239. Kornguth S. Neuronal proteins and paraneoplastic syndromes. N Engl J Med 1989; 321:1607.
240. Schuffler MD, Baird HW, Fleming CR et al. Intestinal pseudo-obstruction as the presenting manifestation of small cell carcinoma of the lung. Ann Intern Med 1983; 98:129.
241. Szabo A, Dalman J, Manley G et al. HuD:a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elar and sex lethal. Cell 1991; 67: 325.
242. Satoyoshi E, Kowa H, Fukunaga N. Subacute cerebellar degeneration and Eaton-Lambert syndrome with bronchogenic carcinoma. Neurology 1973; 23: 764.
243. Schraufnagel DE, Hill R, Leech JA et al. Superior vena caval obstruction: is it a medical emergency. Am J Med 1981; 70: 1169.
244. Spiro SG, Shah S, Harper PG et al. Treatment of obstruction of the superior vena cava by combination chemotherapy with or without irradiation in small cell carcinoma of the bronchus. Thorax 1983; 38: 501.
245. Jahangiri M, Taggart D, Goldstraw P. Role of mediastinoscopy in superior vena caval obstruction. Cancer 1993; 71: 3006.
246. Jackson JE, Brooks DM. Stenting of superior vena caval obstruction. Thorax 1995; 50 (Suppl 1): S31.
247. Ostler PJ, Clarke DP, Watkinson AF et al. Superior vena cava obstruction: a modern management strategy. Clin Oncol 1997; 9: 83.
248. Armstrong B, Perez C, Simpson J et al. Role of irradiation in management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13: 531.
249. Perez C, Presant CA, Van Amberg AL. Management of superior vena cava syndrome. Semin Oncol 1978; 5: 123.
250. Charnsangavej C, Carrasco CH, Wallace S et al. Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 1986; 161: 295.
251. Watkinson AF, Hansell DM. Expandable Wallstent for the treatment of obstruction of the superior vena cava. Thorax 1993; 48: 915.
252. Gaines PA, Belli A-M, Anderson PB et al. Superior vena caval obstruction managed by the Gianturco 2 stent. Clin Radiol 1994; 49:202.
253. Robinson L, Jackson J. New approach to superior vena cava obstruction. Br Med J 1994; 308: 1697.
254. Pancoast HK. Superior pulmonary sulcus tumor. JAMA 1932; 99: 1391.
255. Shaw RR, Paulson DL, Kee JL. Treatment of the superior sulcus tumor by irradiation followed by resection. Ann Surg 1961; 154:29.
256. Hilaris BS, Martini N. Multimodality therapy of superior sulcus tumors. Adv Pain Res Ther 1982; 4: 113.
257. Neal CR, Amdur RJ, Mendenhall WM et al. Pancoast tumor: radiation therapy alone versus preoperative radiation therapy and surgery. Int J Radiat Oncol Biol Phys 1991; 21:651.
258. Komaki R, Roh J, Cox JD, Lopes DA, Conceicao A. Superior sulcus tumors:results of irradiation of 36 patients. Cancer 1981; 48: 1563.
259. Walshe AD, Douglas JG, Kerr KM et al. An audit of the clinical investigation of pleural effusion. Thorax 1992; 47: 734.
260. Martini N, Bains MS, Beattie EJ. Indications for pleurectomy in malignant effusion. Cancer 1975; 35: 734.
261. Wallach HW. Intrapleural tetracycline for malignant pleural effusions. Chest 1975; 68:510.
262. Cox JD, Yesner RA. Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am Rev Respir Dis 1979; 120: 1025.
263. Tarnoff JF, Calinog TA, Byla JG. Prolonged survival following cerebral metastasis from pulmonary cancer. J Thorac Cardiovasc Surg 1976; 72: 933.
264. Mussi A, Janni A, Pistolesi M et al. Surgical treatment of primary lung cancer and solitary brain metastases. Thorax 1985; 40: 191.
265. Borgelt B, Gelber R, Kramer S et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1.
266. Deeley TJ, Rice-Edwards JM. Radiotherapy in the management of cerebral secondaries from bronchial carcinoma. Lancet 1968; i:1209.
267. Baraka ME. Malignant tumours of the trachea. Ann R Coll Surg Engl 1984; 66: 27.
268. Pearson FG, Thompson DW, Weissberg D et al. Adenoid cystic carcinoma of trachea. Ann Thorac Surg 1974; 18: 16.
269. Stalpaert G, Deneffe G, Van Maele R. Surgical treatment of adenoid cystic carcinoma of the left main bronchus and trachea by left pneumonectomy, resection of 7.5 cm trachea, and direct reanastomosis of right lung. Thorax 1979; 34: 554.
270. Macha HN, Koch K, Stadler M et al. New technique for treating occlusive and stenosing tumours of the trachea and main bronchi: endobronchial irradiation by high dose iridium-192 combined with laser canalisation. Thorax 1987; 42: 511.
271. George J. Endoscopic laser resection for tracheobronchial malignancy. Lung Cancer Therapy 1996; 13: 437.
272. George PJM, Garrett CPO, Hetzel MR. Role of the neodymium YAG laser in the management of tracheal tumours. Thorax 1987; 42:440.
273. Westaby S, Jackson JW, Pearson FG. Abifurcated silicone rubber stent for relief of tracheobronchial obstruction. J Thorac Cardiovasc Surg 1982; 83: 414.
274. Fergusson RJ, Cull A. The measurement of quality of life in patients undergoing treatment for lung cancer. Thorax 1991; 46: 671.
275. Montazeri MPH, Gillis CR, McEwen J. Quality of life in patients with lung cancer. Areview of the literature from 1970 to 1995. Chest 1998; 113: 467.
276. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients. Chest 1991; 99: 216.
277. Karnofsky DA, Abelmann WH, Craver LF et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634.
278. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
279. Zubrod CG, Schneiderman M, Frei E et al. Appraisal of methods for the study of chemotherapy of cancer in man. J Chron Dis 1960; 11: 7.
280. Aaronson NK, Ahmedzai S, Bergmann B et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365.
281. Bergman B. The EORTC QLQ Lung Cancer Module: a preliminary analysis. Internal report to the EORTC Qualify of Life Study Group, 1992.
282. de Haes KJM, Van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034.
283. Zigmond AS, Snaith RD. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361.
284. Greenberg ER, Chute CG, Stukel T et al. Social and economic factors in the choice of lung cancer treatment. N Engl J Med 1988; 318: 612.
285. Jennett B, Buxton M. When is treatment for cancer economically justified? Discussion paper. J R Soc Med 1990; 83: 25.
286. Huhti E, Sutinen S, Saloheimo M. Survival among patients with lung cancer: an epidemiologic study. Am Rev Respir Dis 1981; 124: 13.
287. Chahinian AP, Israel L. Rates and patterns of growth of lung cancer. In: Israel L, Chahinian AP, eds. Lung Cancer: Natural History, Prognosis, and Therapy. New York:Academic Press, 1976.
288. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 1979; 73: 1.
289. Meyer JA. The concept and significance of growth rates in human pulmonary tumors. Ann Thorac Surg 1972; 14: 309 1983.
290. Strauss MJ. Growth characteristics of lung cancer. In: Strauss MJ, ed. Lung Cancer:Clinical Diagnosis and Treatment. New York:Grune & Stratton, 1983.
291. Joseph WL, Morton DL, Adkins PC et al. Prognostic significance of tumour doubling times in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg 1971; 61: 23.
292. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol 1956; 76: 988.
293. Bailar JC. Screening for lung cancer: where are we now? Am Rev Respir Dis 1984; 130:545.
294. Berlin NI, Buncher CR, Fontana RS et al. The National Cancer Institute co-operative early lung cancer detection program; results of the initial screen (prevalence); early lung cancer detection: introduction. Am Rev Respir Dis 1984; 130: 545.
295. Frost JK, Ball WC, Levin ML et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130: 549.
296. Fontana RS, Sanderson DR, Taylor WF et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 1984; 130: 561.
297. Bignall JR, Martin M, Smithers DW. Survival in 6086 cases of bronchial carcinoma. Lancet 1967; i: 1067.
298. National Cancer Institute. Cancer Patient Survival Report No. 5. Bethesda, Maryland:National Cancer Institute, 1976.
299. Mountain CF. Value of the new TNM staging system for lung cancer. Chest 1989; 96 (Suppl 1): 47S.
300. Albain KS, Crowley JJ, Leblanc M et al. Survival determinants in extensive stage nonsmall cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 91: 1618.
301. Ludwig Lung Cancer Study Group. Prognostic factors in operable non-small cell lung cancer. In: Proceedings of the UICC Conference on Clinical Oncology. Geneva: International Union Against Cancer, 1981.
302. Kato Y, Ferguson TB, Bennett DE et al. Oat cell carcinoma of the lung. Cancer 1969; 23:517.
303. Hyde L, Yee J, Wilson R, Patno ME. Cell type and the natural history of lung cancer. JAMA 1965; 193: 140.